Figure 2 from Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials

figure

posted on 2025-02-11, 10:00 authored by Angélique Vienot, Dewi Vernerey, Adeline Bouard, Elodie Klajer, Stefano Kim, Christophe Tournigand, Christophe Louvet, Thierry André, Benoît Rousseau, Mylène Wespiser, Laurie Spehner, Ying A. Wang, Anke Weispfenning, Emmanuelle Dochy, Christophe Borg

OS according to baseline STC1 plasma levels (optimized cut-off*) in patients with chemorefractory mCRC in the CORRECT study. A, Overall cohort (N = 646). B, Regorafenib cohort (n = 435). C, Placebo cohort (n = 211). *Optimized STC1 plasma levels: STC1 low: <1,436.87 pg/mL; STC1 high: ≥1,436.87 pg/mL.

History

ARTICLE ABSTRACT

STC1 is a protein secreted by intratumor endothelial cells in which plasma concentrations increase in patients with chemorefractory mCRC. Based on analyses of patients with refractory mCRC in the TEXCAN and CORRECT trials, we found that STC1 plasma levels had a prognostic role for OS, with high levels associated with poor outcome. A predictive role for baseline STC1 levels was pointed out for regorafenib efficacy.

Usage metrics

Keywords

Biomarkers Colorectal Cancer Gastrointestinal Cancers Prognostic Biomarkers Translational Research

Licence

CC BY